Presynaptic Imaging in Major Depressive Episodes After COVID-19
Overview
- Phase
- Not Applicable
- Intervention
- [11C]DTBZ PET scan
- Conditions
- Long COVID
- Sponsor
- Centre for Addiction and Mental Health
- Enrollment
- 90
- Locations
- 1
- Primary Endpoint
- Synaptic Vesicle Glycoprotein 2A Total Distribution Volume (SV2A VT)
- Status
- Recruiting
- Last Updated
- 2 months ago
Overview
Brief Summary
The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.
Detailed Description
Participants will undergo two positron emission tomography (PET) scans, one \[11C\]DTBZ scan (for vesicular monoamine transporter 2 (VMAT2) and one \[18F\]SDM8 scan (for synaptic vesicle glycoprotein 2A (SV2A)), as well as one magnetic resonance imaging (MRI) scan. The main question\[s\] it aims to answer are: 1. The investigators will determine if VMAT2 binding potential (VMAT2 BPND) is reduced in ventral striatum and dorsal putamen in COVID-DNP. 2. The investigators will determine if SV2A total distribution volume (SV2A VT) is reduced in ventral striatum and dorsal putamen in COVID-DNP
Investigators
Jeff Meyer
Scientist and Head, Neurochemical Imaging Program in Mood and Anxiety Disorders, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute
Centre for Addiction and Mental Health
Eligibility Criteria
Inclusion Criteria
- •New onset MDE within 3 months after mild or moderate COVID-19, with MDE verified by the research version SCID for DSM
- •See "Positive COVID-19 diagnosis" listed after inclusion/
Exclusion Criteria
- •for a description of how this is determined.
- •Age 18 to
- •Good general physical health with no active medical conditions based on self-report (except migraine or PASC).
- •Exclusion Criteria:
- •Use of antidepressants in the previous month (6 weeks for fluoxetine).
- •Use of stimulant medication affecting dopamine release in the previous month
- •Use of antipsychotics in the previous month
- •History of neurological disease (except migraine, and PASC) based on self-report
- •Use of medications or herbal products or natural health products with central nervous system effects in past 2 weeks based on self-report
- •Presence of cigarette smoking in the past two months, based on self-report
Arms & Interventions
COVID-DNP
Participants that have recovered from mild or moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
Intervention: [11C]DTBZ PET scan
COVID-DNP
Participants that have recovered from mild or moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
Intervention: [18F]SDM8 PET scan
COVID-DNP
Participants that have recovered from mild or moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
Intervention: MRI scan
Healthy Control
Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.
Intervention: [11C]DTBZ PET scan
Healthy Control
Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.
Intervention: [18F]SDM8 PET scan
Healthy Control
Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.
Intervention: MRI scan
Outcomes
Primary Outcomes
Synaptic Vesicle Glycoprotein 2A Total Distribution Volume (SV2A VT)
Time Frame: within 3 to 4 weeks after initiation of screening
The investigators will determine if SV2A VT is changed in ventral striatum and dorsal putamen in COVID-DNP
Vesicular Monoamine Transporter 2 Binding Potential (VAMT2 BPND)
Time Frame: within 3 to 4 weeks after initiation of screening
The investigators will determine if VMAT2 BPND is changed in ventral striatum and dorsal putamen in COVID-DNP.